[go: up one dir, main page]

PE20050222A1 - Compuestos de triazol como antagonistas de vasopresina - Google Patents

Compuestos de triazol como antagonistas de vasopresina

Info

Publication number
PE20050222A1
PE20050222A1 PE2004000165A PE2004000165A PE20050222A1 PE 20050222 A1 PE20050222 A1 PE 20050222A1 PE 2004000165 A PE2004000165 A PE 2004000165A PE 2004000165 A PE2004000165 A PE 2004000165A PE 20050222 A1 PE20050222 A1 PE 20050222A1
Authority
PE
Peru
Prior art keywords
alkyl
tetraaza
benzo
chloro
ring
Prior art date
Application number
PE2004000165A
Other languages
English (en)
Inventor
Justin Stephen Bryans
Patrick Stephen Johnson
Alan Stobie
Thomas Ryckmans
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20050222A1 publication Critical patent/PE20050222A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE TRIAZOL DE FORMULA (I), DONDE V ES -(CH2)d(O)e-, -CO-, O -CH(ALQUILOC1-C6); W ES -O-, -S(O)a- O -N(R1)-; R1 ES H, ALQUILO(C1-C6), (CH2)bCOR2, CO(CH2)bNR2R3, SO2R2, (CH2)cOR2, (CH2)cNR2R3 O (CH2)bhet1; het1 ES UN HETEROCICLO DE 3 A 8 ATOMOS QUE PUEDE CONTENER O, N O S, OPCIONALMENTE SUSTITUIDOS CON ALQUILO(C1-C6); X E Y SON H, ALQUILO(C1-C6), HALOGENO, OH, CF3, OCF3, OR4; Z ES -(CH2)f(O)g-, -CO-, O -CH(ALQUILO(C1-C6))-; EL ANILLO A ES UN HETEROCICLO SATURADO QUE CONTIENE N, DE 4 A 7 MIEMBROS OPCIONALMENTE SUSTITUIDO CON OH Y AL MENOS UN N DEL ANILLO PUEDE ESTAR SUSTITUIDO CON O; EL ANILLO B ES UN FENILO O UN HETEROCICLO INSATURADO QUE CONTIENE N, DE 4 A 7 MIEMBROS, OPCIONALMENTE SUSTITUIDO CON OH, HALOGENO, CN, CONH2, CF3, OCF3, Y AL MENOS UN N PUEDE ESTAR SUSTITUIDO CON O. SON COMPUESTOS PREFERIDOS: TRICLOROHIDRATO DE 8-CLORO-5-METIL-1-(3,4,5,6-TETRAHIDRO-2H-[1,2']BIPIRIDINIL-4-IL)-5,6-DIHIDRO-4H-2,3,5,10b-TETRAAZA-BENZO[e]AZULENO, 8-CLORO-5-METANOSULFONIL-1-(3,4,5,6-TETRAHIDRO-2H-[1,2']-BIPIRIDINIL-4-IL)-5,6-DIHIDRO-4H-2,3,5,10b-TETRAAZA-BENZO[e]AZULENO, DIMETILAMINO DEL ACIDO 8-CLORO-1-(1-PIRIMIDIN-2-IL-PIPERIDIN-4-IL)-4H,6H-2,3,5,10b-TETRAAZA-BENZO[e]AZULENO-5-SULFONICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE ELABORACION Y COMPUESTOS INTERMEDIOS. UNA FORMULACION FARMACEUTICA QUE LOS CONTIENE. ESTOS COMPUESTOS MUESTRAN UNA ACTIVIDAD ANTAGONISTA DE VASOPRESINA Y PUEDEN USARSE EN EL TRATAMIENTO DE DISMENORREA
PE2004000165A 2003-02-19 2004-02-17 Compuestos de triazol como antagonistas de vasopresina PE20050222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0303852.8A GB0303852D0 (en) 2003-02-19 2003-02-19 Triazole compounds useful in therapy

Publications (1)

Publication Number Publication Date
PE20050222A1 true PE20050222A1 (es) 2005-04-13

Family

ID=9953327

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000165A PE20050222A1 (es) 2003-02-19 2004-02-17 Compuestos de triazol como antagonistas de vasopresina

Country Status (11)

Country Link
CN (1) CN1751047A (es)
AR (1) AR043210A1 (es)
CL (1) CL2004000293A1 (es)
GB (1) GB0303852D0 (es)
GT (1) GT200400020A (es)
NL (1) NL1025527C2 (es)
PA (1) PA8596101A1 (es)
PE (1) PE20050222A1 (es)
TW (1) TW200500367A (es)
UY (1) UY28201A1 (es)
WO (1) WO2004074291A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325021D0 (en) * 2003-10-27 2003-12-03 Pfizer Ltd Therapeutic combinations
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
DE102004001871A1 (de) * 2004-01-14 2005-09-01 Bayer Healthcare Ag Tricyclische Benzazepin-Derivate und ihre Verwendung
MX2007002248A (es) 2004-08-25 2008-10-02 Pfizer Triazolobenzodiazepinas y su uso como antagonistas de vasopresina.
WO2006114706A1 (en) * 2005-04-26 2006-11-02 Pfizer Limited Triazole derivatives as vasopressin antagonists
HRP20121060T1 (hr) 2008-11-13 2013-01-31 F. Hoffmann - La Roche Ag Spiro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azuleni
PE20110590A1 (es) * 2008-11-18 2011-08-31 Hoffmann La Roche Alquilciclohexileteres de dihidrotetraazabenzoazulenos
MY150837A (en) 2008-11-28 2014-02-28 Hoffmann La Roche Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists
CA2756871A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
CA2779088A1 (en) * 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
US8420633B2 (en) * 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) * 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) * 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) * 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) * 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes
US9006450B2 (en) * 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
UY33650A (es) 2010-10-07 2012-04-30 Takeda Pharmaceutical Compuestos heterocíclicos
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
US8828989B2 (en) * 2011-09-26 2014-09-09 Hoffmann-La Roche Inc. Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists
CN103842365B (zh) * 2011-10-05 2017-06-23 霍夫曼-拉罗奇有限公司 作为V1a拮抗剂的环己基‑4H，6H‑5‑氧杂‑2，3，10b‑三氮杂‑苯并[e]薁
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
CN102766674A (zh) * 2012-07-25 2012-11-07 辉源生物科技（上海）有限公司 食蟹猴抗利尿激素受体v1a拮抗剂筛选平台的建立
CA2878442A1 (en) 2012-09-25 2014-04-03 F. Hoffmann-La Roche Ag Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
CN105492010B (zh) 2013-08-19 2020-01-03 豪夫迈·罗氏有限公司 用于治疗相移睡眠障碍的V1a拮抗剂
PE20160845A1 (es) 2013-11-26 2016-09-10 Hoffmann La Roche Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo
MY175464A (en) 2013-12-05 2020-06-29 Hoffmann La Roche Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof
HUE046820T2 (hu) 2014-03-26 2020-03-30 Hoffmann La Roche Biciklusos vegyületek autotaxin (ATX) és lizofoszfatidsav (LPA) termelésgátlókként
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX377277B (es) 2015-09-04 2025-03-07 Hoffmann La Roche Derivados de fenoximetilo.
RU2725138C2 (ru) 2015-09-24 2020-06-30 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca)
BR112018006034A2 (pt) 2015-09-24 2018-10-09 Hoffmann La Roche compostos bicíclicos como inibidores de atx
MA42923A (fr) 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
KR20190129924A (ko) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
US11186577B2 (en) * 2017-06-05 2021-11-30 Blackthorn Therapeutics, Inc. Vasopressin receptor antagonists and products and methods related thereto
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) * 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
CN111170983B (zh) * 2019-12-26 2021-07-09 中国农业大学 一种苄硫基乙酰胺类化合物及其制备方法与应用
CN114644635B (zh) * 2020-12-21 2023-02-03 上海济煜医药科技有限公司 三氮唑类三并环衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823475D0 (en) * 1988-10-06 1988-11-16 Merck Sharp & Dohme Chemical compounds
US5438035A (en) * 1994-06-24 1995-08-01 American Cyanamid Company Methods for controlling undesirable plant species with benzodiazepine compounds
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
BR9713253A (pt) * 1996-11-01 1999-11-03 American Home Prod Derivados de 3-carboxamida de 5h-pirrol [2,1-c][1,4]-benzodiazepinas
PT1147115E (pt) * 1999-01-19 2004-02-27 Ortho Mcneil Pharm Inc Benzodiazepinas triciclicas como antagonistas do receptor da vasopressina
US7109193B2 (en) * 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists

Also Published As

Publication number Publication date
CL2004000293A1 (es) 2005-01-07
PA8596101A1 (es) 2005-08-04
AR043210A1 (es) 2005-07-20
UY28201A1 (es) 2004-09-30
TW200500367A (en) 2005-01-01
CN1751047A (zh) 2006-03-22
GT200400020A (es) 2004-09-21
GB0303852D0 (en) 2003-03-26
WO2004074291A1 (en) 2004-09-02
NL1025527A1 (nl) 2004-08-23
NL1025527C2 (nl) 2005-03-14

Similar Documents

Publication Publication Date Title
PE20050222A1 (es) Compuestos de triazol como antagonistas de vasopresina
ES2125377T3 (es) Azaheterociclicos triciclicos n-acilatados utiles como antagonistas de vasopresina.
AR022230A1 (es) Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
AP1965A (en) Tropane derivatives useful in therapy.
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
EA200400054A1 (ru) Замещенные нафтилиндольные производные в качестве ингибиторов ингибитора активатора плазминогена типа 1 (pai-1)
UY27109A1 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
ATE365740T1 (de) Substituierte pyrazolopyrimidine
PE20070018A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
DK1546134T3 (da) Piperazinsubstituerede arylbenzodiazepiner
PE20080706A1 (es) Arilmidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
NZ509321A (en) Use of an estrogen agonist/antagonist to treat conditions responsive to estrogen such as rheumatoid arthritis, colon cancer, tissue wounds and cataracts
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
PE20020179A1 (es) DERIVADOS DE (6S,9R,10S,11S,13S,16R, 17R)-9-CLORO-6-FLUORO-11-HIDROXI-10,13,16-TRIMETIL-3-OXO-6,7,8,9,10,11,12,13,14,15,16,17-DODECAHIDRO-3H-CICLOPENTA[a]FENANTRENO CARBOXILICO
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
BR0317294A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários
ATE416767T1 (de) 5-halo-tryptaminderivate als 5-ht6 und/oder 5-ht7 rezeptorliganden
PA8495101A1 (es) Derivados de 13-metileritromicina
DE60024414D1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
TR200002380T2 (tr) Yeni triazolo (4,5-d) pirimidin bileşikleri
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
AR035452A1 (es) Sales farmaceuticamente aceptables de compuestos antiarritmicos, procedimiento para la preparación de estas sales, formulación farmaceutica y el uso de estos compuestos para la manufactura de medicamentos para el uso en la profilaxis o el tratamiento de una arritmia
TR200101711T2 (tr) Antihistaminik spiro bileşikler.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed